52.95 +0.85 (1.63%)
After hours: 5:12PM EST
|Bid||52.60 x 200|
|Ask||54.50 x 200|
|Day's range||51.35 - 57.60|
|52-week range||14.70 - 57.75|
|PE ratio (TTM)||N/A|
|Earnings date||12 Mar 2018 - 16 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.42|
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously received European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of SCD.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck & Co. Inc. “Wendy is an accomplished biopharmaceutical executive with a proven track record in building and leading organizations, and has significant expertise in pre- and post-launch strategy and marketing of new therapies,” said Ted W. Love, M.D., president and chief executive officer of GBT.
More than 50 years after the cause of sickle-cell disease was discovered, a dozen treatments for the painful and life-shortening inherited condition offer hope for long-overlooked patients.
A Relative Strength Rating upgrade for Global Blood Therapeutic shows improving technical performance.